AstraZeneca Reports Mixed Lung Cancer Trial Outcomes From Three Pivotal Studies
AstraZeneca reports mixed lung cancer trial data, highlighting successes for Tagrisso and Enhertu while halting a volrustomig study.
Read original at benzingaStocks · News reference
Reported Sunday, HUTCHMED Says ORPATHYS Plus TAGRISSO Achieved Statistically Significant, Clinically Meaningful PFS And OS Improvements In MET-Driven EGFR-Mutated Lung Cancer
First global Phase III trial to show significant progression-free and overall survival benefits in this setting SAFFRON trial results reinforce TAGRISSO® as the backbone therapy across EGFRm lung cancer
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Aug 17, 2026, 6:31 AM
- Checked
- Aug 17, 2026, 6:31 AM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading